Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
Background: Aboriginal children living in remote communities are at high risk of early and persistent otitis media. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are primary pathogens. Vaccines with potential to prevent early OM have not been evaluated in this population. W...
Main Authors: | Amanda Jane Leach, Edward Kim Mulholland, Mathuram Santosham, Paul John Torzillo, Peter McIntyre, Heidi Smith-Vaughan, Nicole Wilson, Beth Arrowsmith, Jemima Beissbarth, Mark D. Chatfield, Victor M. Oguoma, Paul Licciardi, Sue Skull, Ross Andrews, Jonathan Carapetis, Joseph McDonnell, Vicki Krause, Peter Stanley Morris |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-04-01
|
Series: | Vaccine: X |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590136221000036 |
Similar Items
-
Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
by: Amanda Jane Leach, et al.
Published: (2021-03-01) -
Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
by: Earnshaw Stephanie R, et al.
Published: (2012-04-01) -
13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01) -
Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children
by: Corinne Levy, et al.
Published: (2021-08-01) -
Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers
by: L A Shpagina, et al.
Published: (2018-11-01)